Novartis

Novartis Foundation Commemorates World Leprosy Day with its Continued Efforts to go the Last Mile Toward Elimination

2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease
Summary: 

  • 2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease

  • New strategy from the Novartis Foundation to accelerate elimination is focused on interrupting transmission of the disease

  • Last year Novartis renewed its commitment with the WHO to donate multidrug therapy to treat leprosy through the year 2020

  • More than 200,000 people are diagnosed with leprosy every year; approximately 10% of those are children, indicating continued spread of the disease
Press Release

  • 2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease

  • New strategy from the Novartis Foundation to accelerate elimination is focused on interrupting transmission of the disease

  • Last year Novartis renewed its commitment with the WHO to donate multidrug therapy to treat leprosy through the year 2020

  • More than 200,000 people are diagnosed with leprosy every year; approximately 10% of those are children, indicating continued spread of the disease

Novartis Releases 2015 Corporate Responsibility Performance Report

Article

Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company’s performance.

The Novartis Foundation and the London School of Hygiene & Tropical Medicine Join Forces to Put Hypertension Care and Management on the Global Health Agenda

Press Release
  • Global Health and hypertension community gather to highlight innovative delivery models for hypertension management in low- and middle-income countries
  • Experts at London-based dialogue event will also focus on potential enablers to scale healthcare delivery models and critical need for evidence generation
  • Deaths from hypertension are estimated at 9.4 million people annually globally, which is equivalent to all infectious diseases combined

Novartis Foundation and Partners Launch New Hypertension Program in Ghana

Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control
Press Release
  • Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control
     
  • Screening and treatment is shifted to the community and technology supports healthcare workers and empowers patient self-management
     
  • More than one quarter of the adult population in Ghana has hypertension, but only 4% of these hypertensive patients have it under control
     

Expanding Access to Affordable Treatments Against Chronic Diseases

Novartis Access hosts second stakeholder dialogue
Article

On May 25, Novartis Access held its second stakeholder dialogue in conjunction with the 2016 World Health Assembly to share first learnings from the Kenya launch, and to continue the discussion on how to address the burden of noncommunicable diseases (NCDs) in lower-income countries. This event is part of the company’s public commitment to transparency and open dialogue with stakeholders as Novartis Access is rolled out.

Kenya First Country to Launch ‘Novartis Access’, Expanding Affordable Treatment Options Against Chronic Diseases

Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country
Summary: 

•    Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries
•    Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1
•    Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key NCDs 

Press Release

•    Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries
•    Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1
•    Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key NCDs 

Eradicating Malaria Through Innovation: Where Next After 2015?

To mark the inception of the "European Year of Development" and explore a renewed global health agenda for malaria post-2015, Novartis organized a debate earlier this year in the European Parliament on eradicating malaria through innovation.
Article

To mark the inception of the "European Year of Development" earlier this year, and explore a renewed global health agenda for malaria post-2015, Novartis organized a debate in the European Parliament on eradicating malaria through innovation. Other speakers included representatives from the European Parliament, the European Commission, the Kenya Medical Research Institute and Medicines for Malaria Venture. 

About the Novartis Malaria Initiative

Learn about the disease and what Novartis is doing to contribute to its eradication
Multimedia with summary

Novartis Launches ‘Novartis Access’, a Portfolio of Affordable Medicines to Treat Chronic Diseases in Lower-income Countries

First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
Summary: 
  • First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
  • Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month
  • Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally1
Press Release
  • First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
  • Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month
  • Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally1

Novartis Foundation Presents Healthcare Models and Disease Elimination Programs at ECTMIH

Novartis and partners will highlight progress towards transforming the health of the poorest populations
Summary: 

Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH
Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients

  • Retrospective contact tracing of former leprosy patients in Cambodia was effective in reducing disability of new patients through earlier diagnosis
  • Electronic supportive supervision of healthcare professionals in Tanzania helped to identify major quality gaps and showed quick improvements in skills
  • First mobile phone-facilitated leprosy detection system helps identify patients in remote areas of the Philippines
Press Release

Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH
Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients

  • Retrospective contact tracing of former leprosy patients in Cambodia was effective in reducing disability of new patients through earlier diagnosis
  • Electronic supportive supervision of healthcare professionals in Tanzania helped to identify major quality gaps and showed quick improvements in skills
  • First mobile phone-facilitated leprosy detection system helps identify patients in remote areas of the Philippines

Pages

Subscribe to Novartis